Citi Maintains a 'Buy' on Gilead Sciences (GILD); Cautiously Optimistic
Tweet Send to a Friend
Citi maintains a 'Buy' on Gilead Sciences Inc (Nasdaq: GILD). Price target $56.
Citi analyst says, "Stakes for darusentan's phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Citi analyst says, "Stakes for darusentan's phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
